Ben Franklin Technology Partners Southeastern PA

Ben Franklin Technology Partners Southeastern PA

Funds Southeastern Pennsylvania technology companies through state-backed incentives and mentorship across manufacturing and life science ventures.

Eligibility · United States · US-PA

Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP-SEP) is a separately incorporated 501(c)(3) organization headquartered in Philadelphia that functions as the southeastern region's primary early-stage technology investor under Pennsylvania's Ben Franklin Technology Partners (BFTP) state initiative. Operating through a state appropriation from the Pennsylvania Department of Community and Economic Development (DCED) via the Ben Franklin Technology Development Authority (BFTDA), BFTP-SEP provides capital, business counsel, and connections to early-stage technology companies in Philadelphia, Bucks, Delaware, Chester, and Montgomery counties. The program operates on a rolling basis with no fixed application deadline.

The primary investment instrument is convertible debt combined with equity warrants, with individual check sizes typically ranging from $50,000 to $500,000 per company. BFTP-SEP targets for-profit technology companies at TRL 2–6 that are headquartered or committed to maintaining majority operations in southeastern Pennsylvania. Both startups and early-stage established technology companies are eligible; higher education institutions and research organizations may also participate. Recipients receive not only capital but also access to business and technical support, technology commercialization services, and the BFTP co-investor network.

BFTP-SEP is one of four regional BFTP entities in Pennsylvania — the others cover northeastern PA (BFTP-NEP), central and northern PA (BFTP-CNP), and western PA (Innovation Works). Applicants must engage the regional BFTP covering their county, not DCED directly. For founders, BFTP-SEP is one of the most accessible early-stage capital sources in the Philadelphia region and a common first institutional investor before Series A. The program's convertible structure with equity warrants means founders should treat it as patient co-investor capital rather than a non-dilutive award.